Forbion European Acquisition Corp.: M&A transaction — Forbion European Acquisition Corp. completes business combination with enGene; combined entity trades as ENGN

On October 31, 2023, each of (i) Mr. Jasper Bos and (ii) Mr. Cyril Lesser resigned as Chief Executive Officer and Chief Financial Officer, respectively, of the Company, effective on October 31, 2023 upon the completion of the Business Combination.

On October 31, 2023, each of (i) Mr. Jasper Bos and (ii) Mr. Cyril Lesser resigned as Chief Executive Officer and Chief Financial Officer, respectively, of the Company, effective on October 31, 2023 upon the completion of the Business Combination.

On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.

On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.

On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.

On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.

On October 31, 2023, Mr. Wouter Joustra resigned as member of the board of directors of the Company, effective upon the completion of the liquidation of the Company under Cayman law, which is expected to take place on or before January 31, 2023.

On October 31, 2023 (the “Closing Date”), Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (“FEAC” or the “Company”), enGene, Inc., a corporation incorporated under the laws of Canada (“enGene”), and enGene Holdings Inc. (New enGene”) consummated the previously announced business combination (the “Business Combination”) pursuant to the Business Combination Agreement

On the Closing Date, New enGene, FEAC, the Sponsor Holders (as defined in the Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, New enGene granted the Sponsor Holders and the enGene Holders certain customary registration rights with respect to their respective Equity Securities (as defined in the Registration Rights Agreement) of New enGene, in each case, on the terms and subject to the conditions described therein.

and (ii) the Administrative Services Agreement, dated as of December 9, 2021, between the Company and the Sponsor, pursuant to which the Sponsor provided the Company with office space, secretarial and administrative services for up to $10,000 per month.

On October 30, 2023, FEAC, enGene, New enGene and Continental Stock Transfer & Trust Company, a New York corporation (“Continental”), entered into that certain Warrant Assignment, Assumption and Amendment Agreement (the “Warrant Assumption Agreement”) pursuant to which New enGene assumed the warrants of FEAC to purchase one FEAC Class A Share at an exercise price of $11.50 per share, subject to adjustment (the “FEAC Warrants,” and as so assumed, “New enGene Warrants”).

in connection with the consummation of the Business Combination, the following material agreements of the Company terminated in accordance with their terms: (i) the Investment Management Trust Agreement, dated as of December 9, 2021, by and between the Company and Continental, pursuant to which Continental invested the proceeds of the Company’s initial public offering in a trust account;